Inj, famotidine, 0.25 mg
Products billed under this code include Famotidine.
Payment limit per 0.25 MG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J1308
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Famotidine | Baxter Healthcare Corporation | 00338-5197-41 | 960 | $8.64 |
| Famotidine | Hikma Pharmaceuticals USA Inc. | 00641-6021-10 | 8000 | $72.00 |
| Famotidine | Hikma Pharmaceuticals USA Inc. | 00641-6022-25 | 2000 | $18.00 |
| Famotidine | Hikma Pharmaceuticals USA Inc. | 00641-6023-10 | 1600 | $14.40 |
| Famotidine | Sagent Pharmaceuticals | 25021-0753-02 | 2000 | $18.00 |
| Famotidine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1375-01 | 80 | $0.72 |
| Famotidine | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1375-02 | 80 | $0.72 |
| Famotidine | FreseniUS Kabi USA, LLC | 63323-0738-09 | 1600 | $14.40 |
| Famotidine | FreseniUS Kabi USA, LLC | 63323-0738-20 | 8000 | $72.00 |
| Famotidine | FreseniUS Kabi USA, LLC | 63323-0739-12 | 2000 | $18.00 |
Show all 16 products
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Famotidine | FreseniUS Kabi USA, LLC | 63323-0739-16 | 2000 | $18.00 |
| Famotidine | Mylan Institutional LLC | 67457-0433-22 | 2000 | $18.00 |
| Famotidine | Mylan Institutional LLC | 67457-0448-43 | 1600 | $14.40 |
| Famotidine | Mylan Institutional LLC | 67457-0457-20 | 8000 | $72.00 |
| Famotidine | Athenex Pharmaceutical Division, LLC | 70860-0751-02 | 2000 | $18.00 |
| Famotidine | Athenex Pharmaceutical Division, LLC | 70860-0753-20 | 8000 | $72.00 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.009 | +$0.001 | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted September 17, 2026 |
| 3Q26 | $0.008 | −$0.001 | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted September 15, 2026 |
| 2Q26 | $0.009 | $0.00 | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted September 15, 2026 |
| 1Q26 | $0.009 | $0.00 | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted September 15, 2026 |
| 4Q25 | $0.009 | $0.00 | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted September 8, 2026 |
| 3Q25 | $0.009 | +$0.001 | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted March 10, 2026 |
| 2Q25 | $0.008 | – | 0.25 MG | Inj, famotidine, 0.25 mg | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026
- 2Q25: 2026-03-10_april-2025-asp-pricing-file.zipposted March 10, 2026